Concepedia

Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use

Annika Belzer, Michael O. Nguyen, Ashita D. Talsania, Jason Haldas, Janellen Smith, Jonathan S. Leventhal

JAMA Dermatology · 2022 · 13 citations · 2 references

Open access

Concepts

PharmacyDermatologyPharmacotherapyHypersensitivityPharmacovigilanceAdverse Drug Event DetectionAdverse Drug Event ReportingAdverse Drug Reaction MonitoringAdverse Drug Reaction ReportingAdverse Event ReportingDrug AllergyCutaneous Adverse EventsDermatologic Adverse EventsDermatologic DisordersDermatologic PharmacologyDermatologic Toxicity AssessmentDermatologic Toxicity GradingSevere Cutaneous Adverse Reactions

Abstract

This case series describes the different dermatologic adverse events that patients experienced while using amivantamab.

References

2

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

Caroline E. McCoach, Ai‐Ming Yu, David R. Gandara et al. · JCO Precision Oncology · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17